LOS ANGELES (Reuters) - Kidney disease patients treated with Merck & Co Inc's cholesterol-lowering drug Vytorin were about 16 percent less likely to have a heart attack or other cardiovascular problem than patients given a dummy pill, according to a new study.
No comments:
Post a Comment